Oxford Pharmagenesis
Oxford Pharmagenesis, a leading consultancy in the pharmaceutical and biotechnology sectors, is headquartered in Great Britain. Founded in 1998, the company has established itself as a trusted partner for clients seeking expertise in medical communications, evidence generation, and strategic consultancy. With a strong presence in Europe and North America, Oxford Pharmagenesis excels in delivering innovative solutions tailored to the unique needs of the life sciences industry. The firm’s core services include scientific writing, publication planning, and health economics, all designed to enhance the visibility and impact of its clients' products. Renowned for its commitment to quality and integrity, Oxford Pharmagenesis has achieved significant milestones, including numerous awards for excellence in medical communications. As a prominent player in the industry, the company continues to shape the future of healthcare communication through its unique blend of scientific expertise and strategic insight.
DitchCarbon Score
How does Oxford Pharmagenesis's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Business Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Oxford Pharmagenesis's score of 6 is lower than 85% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Oxford Pharmagenesis's reported carbon emissions
Oxford PharmaGenesis, headquartered in the United Kingdom, has set ambitious climate commitments despite not having specific carbon emissions data available for the most recent year. The company has committed to reducing its absolute Scope 1 and Scope 2 greenhouse gas (GHG) emissions by 42% by the fiscal year 2030, using the fiscal year 2023 as a baseline. Additionally, Oxford PharmaGenesis aims for 82% of its suppliers, based on emissions from purchased goods and services, capital goods, and business travel, to have science-based targets by the fiscal year 2028. These targets align with the necessary reductions to limit global warming to 1.5°C, demonstrating the company's commitment to sustainability and responsible environmental stewardship.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Oxford Pharmagenesis is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
